Beyond colchicine, biologic agents such as anakinra (IL-1 receptor antagonist) and tocilizumab (IL-6 inhibitor) have shown promise in treating secondary amyloidosis in systemic autoinflammatory diseases, including SJIA [11,15]. This evidence concerns the gene IL6 and AA amyloidosis.